Vaxcyte is a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide. The Company’s cell-free protein synthesis platform, comprising the XpressCFTM platform, exclusively licensed from Sutro Biopharma, Inc., together with Vaxcyte’s proprietary know-how, enables the design and production of protein carriers and antigens, the critical building blocks of vaccines, in ways that the Company believes conventional vaccine technologies currently cannot. In addition to its pneumococcal conjugate vaccines in development, VAX-24 and VAX-XP, Vaxcyte is leveraging its proprietary platform to advance other novel vaccines, including a prophylactic vaccine to prevent Group A Strep infections (VAX-A1) and a therapeutic vaccine to treat periodontal disease (VAX-PG).

The Max Planck Society for the Advancement of Science (German: Max-Planck-Gesellschaft zur Förderung der Wissenschaften e. V.; abbreviated MPG) is a non-governmental and non-profit association of Research Institutes publicly funded by the federal and the state governments of Germany. Additionally, the Max Planck Society and its Institutes receive third party funding from public and private contributions and from the European Union. The world leading organization is named in honor of its former president, theoretical physicist Max Planck. The 86 Institutes and Research Facilities of the Max Planck Society (as of 2020) conduct basic research in the natural sciences, life sciences, social sciences, and the arts and humanities. They have a total staff of approximately 24,000 permanent employees, including 15,000 scientists, and around 5,000 non-tenured scientists and guests. As of December 31, 2018, the proportion of female employees was 44.4 percent. The Max Planck Society (with its 86 Max Planck Institutes) has a world-leading reputation as a science and technology research organization, with more than 33 Nobel Prizes awarded to its scientists, and is widely regarded as one of the foremost basic research organizations in the world.

DKFZ Deutsche Krebsforschungszentrum is a German private company that operates as a cancer research center.

Beijing Human Intelligent Manufacturing Technology Co., Ltd., established on 2021-09-28, Business scope includes general items:Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;copyright agent;Socioeconomic Advisory Services;Information Consulting Service(Not including licensing information consulting services);Professional Design Services;business management;Medical Research and Experimental Development;Sales of Class II Medical Devices;Sales of Class I Medical Devices;Production of Class I Medical Devices.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)licensed items:Class III medical device business;Production of Class II Medical Devices;Production of Class III Medical Devices.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)(Do not engage in the business activities of projects prohibited and restricted by the industrial policies of the state and this city.)

Beijing Anbiqi Biotechnology Co., Ltd., established on 2010-08-05, The scope of business includes the production of the second category,Class III medical devices;sell food;Sales of Class III Medical Devices;production of medicines(Production of biological products for diagnostic use only);technology development,Technology Promotion,technology transfer,technical consulting,Technical Services;Diagnostic biological products,Development of diagnostic reagents;Import and export,Technology Import and Export,Agent import and export;Sales of machinery and equipment,Chemical Products(Free of Hazardous Chemicals),Class I medical device,Class II medical device;lease commercial premises,office(Shall not be used as premises for tangible market operations);health management,Health Advisory(Except for medical treatment activities subject to approval);Production of Class I medical devices.(Market entities independently choose business projects in accordance with the law,Carry out business activities;Sales of Food Production Class II,Class III medical devices;Sales of Class III Medical Devices;production of medicines(Production of biological products for diagnostic use only).Items subject to approval by law,Carry out business activities in accordance with the approved content after approval by relevant departments;Do not engage in the business activities of projects prohibited and restricted by the industrial policies of the state and this city.)

Xi'an Jinpeng Seedling Co., Ltd., established on 2001-12-04, Business scope includes general items:production of agricultural products,Sales,processing,transportation,Storage and other related services;vegetable planting.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)licensed items:Crop Seed Management.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results)

EpimAb Biotherapeutics, Inc. is a Chinese company located in Shanghai that develops bispecific antibodies. It was founded in 2016 by Chen Bing Wu, who has been the CEO since the inception date.\nThe company says this about itself: EpimAb Biotherapeutics is a privately-owned biopharmaceutical R&D company with research and manufacturing facilities in Shanghai and Suzhou with a proprietary unique and efficient technology called FIT-Ig® (Fabs-In-Tandem Immunoglobulin) to generate bispecific molecules with antibody-like properties. With this platform EpimAb is creating a pipeline of its own novel bispecific antibody therapeutics focused around immuno-oncology and other areas of high value to patients. EpimAb is also committed to diversifying its pipeline through selective licensing of its platform and pipeline assets to partners worldwide.

Nanjing Human Intelligent Manufacturing Technology Co., Ltd., established on 2022-01-12, Business scope includes general items:software development;software sales;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Sales of Class I Medical Devices;Sales of Class II Medical Devices;Technology promotion and application services;Retailing of computer software, hardware and auxiliary equipment;brand management;internet data service;Natural science research and experimental development;Import and export;Technology Import and Export;Import and export agency;Furniture Installation and Repair Services;Computer and Office Equipment Repair;General Equipment Repair;Special Equipment Repair;Daily Product Repair(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

Denka Seiken started out as a manufacturer of vaccines for human use. Later, they became involved with diagnostic reagents and expanded the scope of their business activities to meet the needs of their customers, offering product lines, service, and knowledge to hospitals and clinics. Denka Seiken has established itself as a manufacturer of vaccines and diagnostic reagents.\nDenka Seiken is engaged in research and development in such fields as bacteriology and virology, immunochemistry, clinical chemistry and food-related diagnostic reagents, in addition to vaccines against influenza, DPT, and other illnesses.

Pfizer Inc. (NYSE: PFE, /ˈfaɪzər/) is an American multinational pharmaceutical corporation headquartered in New York City was founded in 1849, based in New York City and was listed on New York Stock Exchange. It is one of the world's largest pharmaceutical companies. It is listed on the New York Stock Exchange, and its shares have been a component of the Dow Jones Industrial Average since 2004. Pfizer ranked No. 57 on the 2018 Fortune 500 list of the largest United States corporations by total revenue.

Fujirebio, Inc. engages in the manufacture, sale, import and export of clinical diagnostic reagents and assay instruments. It also provides diagnostic, clinical laboratory testing and related services. The company was founded on December 18, 1950 and is headquartered in Tokyo, Japan.

Wuhan Tangzhi Pharmaceutical Co., Ltd., established on 2019-04-23, Business scope includes drugs,Drug intermediate,API,Chemical raw materials and products(Free of Hazardous Chemicals),Research and development of drug therapy technology;laboratory reagent(Free of Hazardous Chemicals)Wholesale and retail;R&D of scientific research reagents,Production,technical consulting,Technical service and wholesale and retail;biology,agriculture,development of medical technology,technical consulting,technology transfer;Wholesale and retail of instruments and meters;Import and export,Technology Import and Export,Agent import and export(Does not contain goods or technologies that are prohibited or restricted from import and export by the state).(Projects subject to approval by law,Business activities can only be carried out after approval by relevant departments)

At Affimed, they are committed to improving outcomes for patients with cancer. Their scientific team has been devoted to unlocking the power of the innate immune system for nearly two decades to provide a unqiue approach to fighting cancer. With their unparalleled expertise in innate immunity and innate cell engager-based medicines, they aim to overcome the limitations and challenges faced by current immuno-oncology (I-O) therapies.

Amgen Inc. (formerly Applied Molecular Genetics Inc.) is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. In 2018, the company's largest selling product lines were Neulasta, an immunostimulator used to prevent infections in patients undergoing cancer chemotherapy and Enbrel, a tumor necrosis factor blocker used in the treatment of rheumatoid arthritis and other autoimmune diseases. Other products include Epogen, Aranesp, Sensipar/Mimpara, Nplate, Vectibix, Prolia and XGEVA.

Manufactures and sells pharmaceuticals

Meso Scale Technologies LLC is a biotechnology company. It provides chemiluminescence based detection technologies and products. The company was founded by Jacob N. Wohlstadter in1995 and is headquartered in Wilmington, DE.

Foshan Dean Medical Laboratory Co., Ltd., established on 2012-04-11, The scope of business includes medical laboratory;clinical body fluid,blood specialty;clinical microbiology major;clinical chemistry laboratory;clinical immunization,Serology major;Clinical Cytomolecular Genetics Major/Pathology;medical technology development,Services and Consulting.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments.)(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Eureka Therapeutics, Inc. develops therapeutic monoclonal antibodies for cancer indication and treatment. It focuses on the discovery of fully-human antibody drugs for the treatment of cancer and utilizing its antibody drug discovery and engineering technologies, and advancing therapies for targeting previously inaccessible cancer antigens. The company was founded by Cheng Liu in 2006 and is headquartered in Emeryville, CA.

Part of Amgen, Inc., Amgen Research (Munich) GmbH is a German company located in Munich. The firm produces copper and metal powders. Robert Saller and Peter Kufer are the current co-CEOs of the firm. On June 13, 2002 ECKA Granulate GmbH & Co. KG acquired Amgen Research (Munich) GmbH from Aurubis AG.

Allogene Therapeutics is a clinical stage immuno-oncology company. It is mainly engaged in the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is involved in developing a pipeline of multiple allogeneic T cell product candidates utilizing validated gene editing and advanced proprietary cell manufacturing technologies. Its pipeline includes UCART19 which is developed for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL), as well as several preclinical allogeneic CAR T therapies.